Navamedic ASA and Orion Corporation signed a license and supply agreement for Flexilev, including the OraFID dispenser, across Europe, not including Sweden, Norway, Denmark, and Iceland, where Navamedic will market and sell the product. Flexilev is a novel prescription treatment for Parkinson's disease and was added to Navamedic's product portfolio following the acquisition of Sensidose AB in May 2023. Through the signed agreement, Orion has been granted the exclusive right to market, distribute, and sell Flexilev in 27 countries in Europe, including the "big five": Germany, France, Italy, Spain and the UK.

Orion will be the marketing authorization (MA) holder in their territory and assume all rights and responsibilities as the MA holder. Navamedic will be responsible for manufacturing and supply of Flexilev in the OraFID dispenser to Orion. The agreement consists of a non-refundable upfront payment of 2mEUR to Navamedic, upon signature of the agreement.

Additionally, Navamedic is entitled to milestone payments of up to EUR 3.5 million upon reimbursement approval in key countries, as well as royalty from net revenue and sales milestone payments.